



Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2

November 25, 2014

Presentation to be webcast on www.exelixis.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 25, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Piper Jaffray 26th Annual Healthcare Conference taking place December 2-3 in New York. The Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on Tuesday, December 2, 2014.

The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at www.exelixis.com.

Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.



Source: Exelixis, Inc.

Exelixis, Inc.

Susan Hubbard, 650-837-8194

Investor Relations & Corporate Communications

shubbard@exelixis.com